Pharma Focus Asia
MasterControl - Avoid Falling Behind the Pharma Market

Antengene Developed World’s First XPOVIO® for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene has approved New Drug Application (NDA) for XPOVIO® (selinexor) in combination with dexamethasone for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) patients who have received multiple prior therapies.

XPOVIO® stands as the world's pioneering orally-available, selective inhibitor of the nuclear export protein XPO1, with its approval marking a groundbreaking milestone. 

Its novel mechanism of action introduces a fresh approach to treatment, complemented by the potential for synergistic effects within combination regimens. Notably, XPOVIO® exhibits rapid onset of action, contributing to its ability to yield prompt and enduring responses in patients.

XPOVIO® (selinexor) in combination with dexamethasone is designed for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have undergone at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs), and an anti-CD38 monoclonal antibody, and who have shown disease progression on the last therapy.

Through its inhibition of the nuclear export protein XPO1, XPOVIO® prompts the accumulation and activation of tumour suppressor proteins and growth-regulating molecules within the cell nucleus. Furthermore, it leads to a reduction in the levels of various oncogenic proteins.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Increasing the likelihood of your drug approvalMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® productsMedical Fair Thailand 20235th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023
MasterControl - 6 Essential Features in an eQMS